Skip to main content
CHRS
NASDAQ Life Sciences

Coherus 10-Q: Going-Concern Doubt With $83.6M Cash After $14.3M Q3 Revenue

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.801
Mkt Cap
$126.32M
52W Low
$0.732
52W High
$2.616
52W Position info
9.5% above low
Off High info
69% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

CHRS is trading near its 52-week low of $0.732 (9.5% above the low).

Summary

Coherus's Q3 10-Q discloses substantial going-concern doubt, with $83.6 million of cash and securities against $154.0 million of nine-month operating cash burn, backstopped by a $55.0 million 2031 term loan and an untouched $50.0 million ATM.


Key Events · Earnings and Guidance · CHRS

  • Going-Concern Doubt Disclosed

    Management concluded that substantial doubt about the ability to continue as a going concern had not been alleviated for the one-year period following issuance of the financial statements.

  • Cash Falls to $83.6 Million

    Cash, cash equivalents and marketable securities totaled $83.6 million at September 30, 2026, versus $172.1 million at December 31, 2025, after $154.0 million of nine-month operating cash burn.

  • Q3 Revenue $14.3 Million

    Total net revenue was $14.274 million for the quarter, with LOQTORZI contributing $14.009 million; nine-month revenue reached $40.891 million versus $29.424 million a year earlier.

  • Debt Refinanced Into 2031 Loan

    The $55.0 million Innovatus Term A Loan was drawn August 14, 2026, repaying the 2029 Term Loan at a $41.2 million payoff and producing a $3.4 million loss on extinguishment; interest-only through September 2029.


Analysis · CHRS · Life Sciences

The 10-Q makes explicit what the earnings release only implied: management concluded that substantial doubt about Coherus's ability to continue as a going concern was not alleviated for the year following issuance. Cash, equivalents and marketable securities fell to $83.6 million from $172.1 million at year-end 2025, while the company burned $154.0 million of operating cash in nine months and carried a $1.5 billion accumulated deficit. The offset is the August refinancing — a $55.0 million Innovatus term loan maturing 2031 with interest-only payments for 36 months — plus a fresh $50.0 million Leerink ATM that has sold nothing yet. With LOQTORZI at $14.0 million for the quarter and a 30% headcount cut underway, the equity is now a bet on tagmokitug's esophageal cancer data and further capital raises.

How filings like this one have moved

In the 30 days to Nov 9, 2026, 47.1% of the 1533 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CHRS was trading at $0.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $126.3M. The 52-week trading range was $0.73 to $2.62. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CHRS - Latest Insights

CHRS
Nov 09, 2026, 4:20 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.7976
Real-time Price: $0.8008 info
Change: +$0.0032 (+0.40%) info
Market Cap: $126.32M info
CHRS
Nov 09, 2026, 4:07 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $0.770
Real-time Price: $0.8008 info
Change: +$0.0308 (+4%) info
Market Cap: $126.32M info
CHRS
Oct 29, 2026, 8:10 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.05
Real-time Price: $0.8008 info
Change: -$0.2492 (-24%) info
Market Cap: $126.32M info
CHRS
Sep 23, 2026, 1:01 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $1.25
Real-time Price: $0.8008 info
Change: -$0.4442 (-36%) info
Market Cap: $126.32M info
CHRS
Aug 17, 2026, 5:36 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $1.23
Real-time Price: $0.8008 info
Change: -$0.4292 (-35%) info
Market Cap: $126.32M info